Saturday Edition
Stay updated with Archyde – your source for breaking news, global headlines, economy, entertainment, health, technology, and sports. Fresh stories daily.
Researchers have developed the first clinically validated “digital twins” of human lungs—virtual replicas capable of predicting transplant success and therapeutic responses. Using ex vivo perfusion (a technique where donor lungs ... Read More
Continuous Coverage
North Carolina’s Piedmont Triad, Ohio’s rustbelt corridors, and the remote frontiers of Maine and Alaska—these are the unlikely…
Notre Dame’s 2026 NCAA East First Round saw AI-driven analytics and cybersecurity protocols under scrutiny, revealing tech trends…
Recent neurobiological research indicates that GLP-1 receptor agonists, such as semaglutide and tirzepatide, exert influence beyond metabolic regulation…
The Criterion Collection’s “Mobile Closet” tour is making a high-profile stop in Portland this weekend, offering cinephiles a…
Chandra X-ray Observatory reveals a pulsar wind nebula within a supernova remnant, offering unprecedented insights into cosmic high-energy…
Companies leveraging AI without mass layoffs, citing examples like IBM and Microsoft, highlight a shift in tech sector…
Global Affairs
The World Health Organization (WHO) has mobilized an urgent response in the Democratic Republic of the Congo (DRC)…
Markets And Money
Gold price for 21k in Egypt fell 6.2% on May 30, 2026, amid tightening monetary policy and weakening…
Digital Culture
Microsoft is teasing new Surface devices at this week’s Build conference, with leaked benchmarks and renderings revealing a…
Science And Wellbeing
Emerging research suggests that GLP-1 receptor agonists—drugs like semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda)—may alleviate symptoms of depression,…
Screen And Sound
As Marilyn Monroe approaches what would have been her 100th birthday on June 1, 2026, a surge of…
Fixtures And Form
Real Madrid’s 1957 European Cup triumph, their second in three years, remains a cornerstone of club lore. As…
